Literature DB >> 23935843

Effect of licochalcone A on growth and properties of Streptococcus suis.

Huaijie Hao1, Wenjia Hui, Peng Liu, Qingyu Lv, Xiaotao Zeng, Hua Jiang, Yanzi Wang, Xin Zheng, Yuling Zheng, Jianchun Li, Xuyu Zhou, Yongqiang Jiang.   

Abstract

Streptococcus suis (S.suis) is an important emerging worldwide pig pathogen and zoonotic agent with rapid evolution of virulence and drug resistance. In this study, we wanted to investigate the effect of licochalcone A on growth and properties of Streptococcus suis. The antimicrobial activity of licochalcone A was tested by growth inhibition assay and the minimal inhibitory concentrations (MICs) also were determined. The effect of licochalcone A on S.suis biofilm formation was characterized by crystal violet staining. The effect of licochalcone A on suilysin secretion was evaluated by titration of hemolytic activity. To understand the antimicrobial effect, gene expression profile of S.suis treated by licochalcone A was analyzed by DNA microarray. Our results demonstrated that licochalcone A showed antimicrobial activity on S.suis with MICs of 4 µg/ml for S.suis serotype 2 strains and 8 µg/ml for S.suis serotype 7 strains. Biofilm formation was inhibited by 30-40% in the presence of licochalcone A (3 µg/ml) and suilysin secretion was also significantly inhibited in the presence of licochalcone A (1.5 µg/ml). The gene expression profile of S.suis in the presence of licochalcone A showed that 132 genes were differentially regulated, and we analyzed the regulated genes in the aspect of the bacterial cell cycle control. Among the deregulated genes, the genes responsible for the mass doubling was increased expression, but the genes responsible for DNA replication and cell division were inhibited the expression. So, we think the regulation of the cell cycle genes might provide a mechanistic understanding of licochalcone A mediated antimicrobial effect against S.suis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23935843      PMCID: PMC3720849          DOI: 10.1371/journal.pone.0067728

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Streptococcus suis (S.suis) is an important emerging worldwide pig pathogen and zoonotic agent causing severe meningitis, pneumonia, and sepsis in pigs and also meningitis and Streptococci toxin-shock-like syndrome (STSLS) in humans [1], [2]. Since the first human infection report in Denmark in 1968, infections in humans were considered sporadic infections in people working with pigs or pork-derived products [3]. However, a large outbreak of S.suis serotype 2 infection that emerged in Sichuan Province, China in 2005 and resulted in 215 cases and 38 deaths among humans, has changed the perspective of the threat posed by this pathogen to human health [4]. For S.suis infection in human, intravenous penicillin G has been used to successfully treat most cases. However, penicillin-resistant strains have been isolated in 6–28% of piglets. On the other hand, the widespread use of antibiotics such as tetracycline in swine feed have been demonstrated to provide the selective pressure for rapid evolution of virulence and drug resistance in S.suis [5], [6]. Up to now, S.suis vaccines for humans do not exist so far and there are also no effective vaccines available even for swine. Licochalcone A is one of the many flavonoids present in the Chinese licorice root, which is used in traditional Chinese medicine. The structure of licochalcone A was first reported in 1975, but no biological activity was described [7]. Later studies have revealed that licochalcone A exhibits antimicrobial, antioxidant and anti-inflammatory activities [8]–[11]. In this study, we investigated the effect and possible mechanism of licochalcone A on growth and properties of S.suis.

Results

Growth of Streptococcus suis in the presence of licochalcone A

The growth curves of S.suis strain 05ZYH33 is shown in Figure 1. The data of bacteria density and colony forming unit (CFU) showed that the growth of bacteria was inhibited in a licochalcone A concentration-dependent manner. At 2 µg/ml, licochalcone A could show the bacteriostatic effect on the growth of S.suis strain 05ZYH33. At 4 µg/ml, licochalcone A completely inhibited bacteria growth.
Figure 1

Effects of licochalcone A on the in vitro growth of S.suis strain 05ZYH33.

(A) the absorbance of bacteria at 600 nm at different time. (B) the viable bacteria number at different time. CFU: colony forming unit.

Effects of licochalcone A on the in vitro growth of S.suis strain 05ZYH33.

(A) the absorbance of bacteria at 600 nm at different time. (B) the viable bacteria number at different time. CFU: colony forming unit. To further evaluate the activity of licochalcone A against S.suis, the MICs of different S.suis strains were determined. As shown in Table 1, licochalcone A was effective for all tested S.suis strains with MIC of 4 µg/ml for S.suis serotype 2 strains and 8 µg/ml for S.suis serotype 7 strains.
Table 1

Antimicrobial activity of licochalcone A against Streptococcus suis.

StrainDescriptiona Originb MIC (µg/ml)
S.suis 05ZYH33 Serotype 2, MRP+EF+SLY+89K+ Sichuan, China HP, 20054
S.suis 5 Serotype 2, MRP+EF+SLY+89K+ Sichuan, China DP, 20054
S.suis 98012 Serotype 2, MRP+EF+SLY+89K+ Jiangsu, China HP, 19984
S.suis 98013 Serotype 2, MRP+EF+SLY+89K+ Jiangsu, China HP, 19984
S.suis 2005001 Serotype 2, MRP+EF+SLY+89K+ Sichuan, China HP, 20054
S.suis 2005002 Serotype 2, MRP+EF+SLY+89K+ Sichuan, China HP, 20054
S.suis sun Serotype 2, MRP+EF+SLY+89K+ Jiangsu, China HP, 20064
S.suis 606 Serotype 2, MRP+EF+SLY+89K China DP, 19804
S.suis 1940 Serotype 2, MRP+EF+SLY+89K China DP, 19804
S.suis 1941 Serotype 2, MRP+EF+SLY+89K China DP, 19804
S.suis NJ Serotype 2, MRP+EF+SLY+89K Jiangsu, China DP4
S.suis S735 Serotype 2, MRP+EF+SLY+89K Netherlands DP4
S.suis 4005 Serotype 2, MRP+EF+SLY+89K Netherlands DP4
S.suis F8-2 Serotype 7Hebei, China HPL8
S.suis B11 Serotype 7Hebei, China HPL8
S.suis M20-1 Serotype 7Hebei, China HPL8
S.suis 68-1 Serotype 7Hebei, China HPL8
S.suis 5B2 Serotype 7Jilin, China HPL8

89K, 89 K pathogenicity islands (PAI).

HP, human patients; DP, diseased piglets; HPL, healthy piglets.

89K, 89 K pathogenicity islands (PAI). HP, human patients; DP, diseased piglets; HPL, healthy piglets.

Licochalcone A inhibits the biofilm formation of Streptococcus suis

Bacterial biofilms are formed when unicellular organisms come together to form a community that is attached to a solid surface and encased in an exopolysaccharide matrix. It has been suggested that this matrix, among other functions, prevents the access of antibiotics to the bacterial cells embedded in the community. When bacteria exist in a biofilm, they can become 10–100 times more resistant to the effects of antimicrobial agents [12], [13]. S.suis is capable of forming a dense biofilm especially in the presence of fibrinogen [14]. In this study, we evaluated the effect of licochalcone A on biofilm formation. Biofilm was stained with crystal violet and the absorbance value at 550 nm was determined the biofilm formation. As shown in Figure 2A and 2C, biofilm formation was inhibited with the increasing the concentration of licochalcone A, and concentration of licochalcone A at 3 µg/ml still had a significant inhibitory effect on biofilm formation. To investigate if the inhibition of biofilm formation in the presence of licochalcone A was due to the retardation of growth, the total cell density (biofilm and planktonic cells) was determined at 18 h or 24 h. As shown in Figure 2B and 2D, it had no significantly influence on the total cell density of S.suis strain 05ZYH33 at the concentration of 3 µg/ml licochalcone A. The above concentration (3 µg/ml) is lower than the MIC values, suggesting a true specific anti-biofilm effect for licochalcone A on S.suis.
Figure 2

Effect of licochalcone A on biofilm formation by S.suis serotype 2 strain 05ZYH33 determined by the microtiter plate assay.

S.suis was cultured in THB medium supplemented with 5 mg/ml human fibrinogen for 18 h (A) or 24 h (C) and biofilm formation was determined in the presence of 0, 2, 3 and 4 µg/ml licochalcone A, respectively. A value of 100% was given to the biofilm formed in the absence of licochalcone A. Assays were performed in triplicate, and the means ± standard deviations of two independent experiments are indicated. The total cell density at 18 h (B) or 24 h (D) also were measured spectrophotometrically (OD600 nm).

Effect of licochalcone A on biofilm formation by S.suis serotype 2 strain 05ZYH33 determined by the microtiter plate assay.

S.suis was cultured in THB medium supplemented with 5 mg/ml human fibrinogen for 18 h (A) or 24 h (C) and biofilm formation was determined in the presence of 0, 2, 3 and 4 µg/ml licochalcone A, respectively. A value of 100% was given to the biofilm formed in the absence of licochalcone A. Assays were performed in triplicate, and the means ± standard deviations of two independent experiments are indicated. The total cell density at 18 h (B) or 24 h (D) also were measured spectrophotometrically (OD600 nm).

Licochalcone A inhibits the release of suilysin

Suilysin is the hemolysin of S.suis serotype 2 encoded by sly (05SSU1403), and is a member of the thiol-activated pore-forming toxin family. Suilysin is actively involved in S.suis infection and host response. During interaction with human cells, suilysin was one component that up-regulated surface molecules of human monocytes [15]. The presence of suilysin could enhance epithelial invasion and cell lysis by virulent strains of S.suis [16]. A further study speculated that suilysin was involved in adherence and cell injury rather than in direct cellular invasion. A retrospective study correlated the presence of the suilysin gene and expression of MRP and EF with high virulence in S.suis serotype 2 isolates [17]. Effect of licochalcone A on suilysin secretion was tested by titration of hemolytic activity. S.suis strain 05ZYH33 was cultured at 37°C for 8 h in the presence of different concentration of licochalcone A. The culture supernatants were collected by centrifugation and tested the hemolytic activity as described in materials and methods. The reciprocal of the highest dilution of a given cell-free supernatant that exhibited at least 50% of RBC lysis was taken as the titre, in hemolytic units (HU), of the suilysin in that sample. As shown in Figure 3A, hemolytic activity of suilysin was significantly decreased when S.suis strain was cultured in the presence of licochalcone A (1.5 µg/ml). At the same time, we measured the bacteria density to investigate if the decrease of suilysin release was due to simply fewer cells present in samples treated with licochalcone A. As shown in Figure 3B, there were nearly same bacteria cells treated with 1.5 µg/ml licochalcone A compared with that of untreated group. These results indicated that licochalcone A could inhibit the secretion of suilysin in S.suis in the presence of 1.5 µg/ml licochalcone A.
Figure 3

Effect of licochalcone A on suilysin secretion of S.suis strain 05ZYH33 determined by hemolytic activity.

A. Culture supernatants of S.suis 05ZYH33 treated by different concentration of licochalcone A were collected and tested the hemolytic activity as described by materials and methods. One hemolytic unit is defined as the reciprocal of the suilysin titre, which was calculated as the highest dilution of the supernatant which caused at least 50% hemolysis. B. The absorbance at 600 nm was recorded to determine the changes in growth and culture density.

Effect of licochalcone A on suilysin secretion of S.suis strain 05ZYH33 determined by hemolytic activity.

A. Culture supernatants of S.suis 05ZYH33 treated by different concentration of licochalcone A were collected and tested the hemolytic activity as described by materials and methods. One hemolytic unit is defined as the reciprocal of the suilysin titre, which was calculated as the highest dilution of the supernatant which caused at least 50% hemolysis. B. The absorbance at 600 nm was recorded to determine the changes in growth and culture density. The mechanism of suilysin regulation is not well clear, and environmental changes such as pH shift, nutrient exhaustion, cell confluence, or other stressful factors may play a role. A transposon mutagenesis study had demonstrated that manN, putative mannose-specific phosphotransferase system component IID encoded by 05SSU1780, repressed the expression of suilysin [18]. In this study, after treated by licochalcone A, we also found that the expression of manN was upregulated in correlation with the down-regulated expression of suilysin in S.suis strain 05ZYH33 (Table 2). These results indicated that manN might be a gene targeted by licochalcone A, and the effect mechanism of licochalcone A on suilysin expression by S.suis was similar to that of licochalcone A on alpha-toxin expression by Methicillin-sensitive Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA), namely targeting the regulation genes [19], [20].
Table 2

List of significant regulated genes of S.suis in the presence of licochalcone A.

Gene IDGene nameCOGFold change* Annotation
Energy production and conversion
05SSU1205 -C2.23Aconitase A
05SSU0280 -C−11.97NAD-dependent aldehyde dehydrogenase
Cell division and chromosome partitioning
05SSU0417 gpsBD−2.06Cell division initiation protein
05SSU0479 -D−2.91Actin-like ATPase involved in cell division
Amino acid transport and metabolism
05SSU0252 -E3.22NAD(P)H-dependent glutamate dehydrogenase
05SSU0791 -E2.05Carbamoylphosphate synthase small subunit
05SSU1026 -E2.12ABC-type amino acid transport/signal transduction system, periplasmic component/domain
05SSU1027 -E2.91ABC-type amino acid transport/signal transduction system, periplasmic component/domain
05SSU1028 -E2.85ABC-type amino acid transport/signal transduction system, periplasmic component/domain
05SSU1029 -E3.21ABC-type polar amino acid transport system, ATPase component
05SSU1361 pyrCE3.33ABC-type polar amino acid transport system, ATPase component
05SSU1362 -E2.22ABC transporter substrate-binding protein - glutamine transport/Major cell binding factor precursor
05SSU1363 -E4.22amino acid ABC transporter, permease protein
05SSU1365 -E3.89ABC-type amino acid transport system, permease component
05SSU1546 -E2.13ABC-type branched-chain amino acid transport system, permease component
05SSU2067 -E3.05putative amino acid ABC transporter, ATP-binding protein
05SSU2068 -E2.81ABC-type amino acid transport system, permease component
05SSU1709 pepCE−2.65cysteine aminopeptidase C
05SSU0345 -E−2.18L-asparaginase/archaeal Glu-tRNAGln amidotransferase subunit D
Nucleotide transport and metabolism
05SSU0091 adkF2.98Adenylate kinase and related kinases
05SSU1207 -F2.12Ribonucleotide reductase, alpha subunit
05SSU1209 nrdFF2.27Ribonucleotide reductase, beta subunit
05SSU1935 -F2.31Xanthine/uracil permease
05SSU2116 -F2.505′-nucleotidase/2′,3′-cyclic phosphodiesterase and related esterases
05SSU2118 -F2.81Oxygen-sensitive ribonucleoside-triphosphate reductase
05SSU0357 -F−2.37deoxyguanosinetriphosphate triphosphohydrolase-related protein
05SSU0491 -F−3.01putative hydrolase (MutT family)
05SSU0661 -F−2.63Thymidylate kinase
05SSU0846 -F−2.07Thymidine kinase
05SSU1971 -F−2.00unknown protein
05SSU1065 -F−2.00Phosphoribosylpyrophosphate synthetase
Carbohydrate transport and metabolism
05SSU1779 manMG2.29mannose-specific PTS IIC
05SSU1780 manNG2.68mannose-specific PTS IID
05SSU1317 -G−2.24hypothetical protein
Coenzyme transport and metabolism
05SSU0689 -H−2.35Phosphopantothenoylcysteine synthetase/decarboxylase
05SSU0835 -H−2.17Dihydrofolate reductase
05SSU1441 hemNH−2.09coproporphyrinogen III oxidase
05SSU1972 -H−2.21Nicotinamide mononucleotide transporter
05SSU1973 -H−2.07unknown protein
Lipid metabolism
05SSU1796 -I2.94Acetyl-CoA carboxylase alpha subunit
05SSU1797 -I2.87Acetyl-CoA carboxylase beta subunit
05SSU1798 -I2.86Acetyl-CoA carboxylase beta subunit
05SSU1799 accCI2.79Biotin carboxylase
05SSU1800 -I2.473-hydroxymyristoyl/3-hydroxydecanoyl-(acyl carrier protein) dehydratase
05SSU1804 -I2.16(acyl-carrier-protein) S-malonyltransferase
Inorganic ion transport and metabolism
05SSU0647 -P2.20ABC-type Fe3+-siderophore transport system, permease component
05SSU1768 -P2.65ABC-type metal ion transport system, permease component
05SSU1769 -P2.44ABC-type metal ion transport system, ATPase component
05SSU0310 Fur/ZurP−3.10Fe2+/Zn2+ uptake regulation protein
05SSU1689 -P−2.43ABC-type molybdenum transport system, ATPase component/photorepair protein PhrA
05SSU1759 -P−2.23potassium uptake protein, Trk family
05SSU1760 -P−2.09K+ transport system, NAD-binding component
05SSU2032 -P−2.30conserved hypothetical protein
Translation, ribosomal structure and biogenesis
05SSU0071 rplCJ2.76Ribosomal protein L3
05SSU0072 rplDJ2.82Ribosomal protein L4
05SSU0073 rplWJ3.12Ribosomal protein L23
05SSU0074 rplBJ3.22Ribosomal protein L2
05SSU0075 rpsSJ3.24SSU ribosomal protein S19P
05SSU0076 rplVJ3.65Ribosomal protein L22
05SSU0077 rpsCJ3.73ribosomal protein S3
05SSU0078 rplPJ3.8350S ribosomal protein L16
05SSU0079 -J3.9150s ribosomal protein L29
05SSU0081 rplNJ4.03Ribosomal protein L14
05SSU0082 rplXJ3.21Ribosomal protein L24
05SSU0083 rplEJ3.84Ribosomal protein L5
05SSU0085 rplFJ3.95Ribosomal protein L6P/L9E
05SSU0086 rplRJ3.39Ribosomal protein L18
05SSU0087 rpsEJ4.52Ribosomal protein S5
05SSU0089 -J4.62Ribosomal protein L15
05SSU0151 -J2.63Ribosomal protein S7
05SSU0152 -J2.51Translation elongation factor (GTPases)
05SSU0983 rplLJ3.11Ribosomal protein L7/L12
05SSU0984 -J2.81Ribosomal protein L10
05SSU1268 rplTJ2.84Ribosomal protein L20
05SSU1269 rpmIJ2.3250S ribosomal protein L35
05SSU1979 tsfJ2.33Translation elongation factor Ts
05SSU1980 rpsBJ2.3930S ribosomal protein S2
05SSU2156 rpsDJ2.6230S ribosomal protein S4
Transcription
05SSU0095 -K2.52DNA-directed RNA polymerase, alpha subunit/40 kD subunit
05SSU0122 -K3.30DNA-directed RNA polymerase, beta' subunit/160 kD subunit
05SSU0395 -K−2.01Transcriptional regulator
05SSU0608 -K−2.10Transcriptional regulator
05SSU1012 -K−2.09Transcriptional regulator
05SSU2056 -K−2.06Transcriptional antiterminator
DNA replication, recombination and repair
05SSU1833 -L2.22putative single-stranded DNA-binding protein
05SSU1047 -L−2.99Integrase
Cell envelope biogenesis, outer membrane
05SSU2099 -M4.42hypothetical protein
05SSU2100 -M6.66Unknown protein
05SSU2103 -M4.47LPXTG-motif cell wall anchor domain protein
05SSU2104 -M4.49hypothetical protein
05SSU0745 -M−2.06D-alanyl-D-alanine carboxypeptidase
05SSU1370 -M−2.24Glycosyltransferase
Posttranslational modification, protein turnover, chaperones
05SSU0149 -O2.04GroEL
05SSU0299 -O2.45Molecular chaperone GrpE (heat shock protein)
05SSU0300 -O2.64Molecular chaperone
05SSU0389 -O2.50ATPases with chaperone activity, ATP-binding subunit
05SSU0390 -O2.70ATPases with chaperone activity, ATP-binding subunit
05SSU1344 -O−2.09Peptidyl-prolyl cis-trans isomerase (rotamase) - cyclophilin family
General function prediction only
05SSU1257 R2.59ABC transporter permease protein
05SSU1894 -R2.06Predicted metal-sulfur cluster biosynthetic enzyme
05SSU2115 -R2.04Predicted acetyltransferase
05SSU0228 -R−2.13Predicted dehydrogenase and related proteins
05SSU0362 -R−2.05Permease of the drug/metabolite transporter (DMT) superfamily
05SSU0279 -R−4.42Zn-dependent alcohol dehydrogenase
05SSU0346 -R−2.03Predicted hydrolase of the HAD superfamily
05SSU0365 -R−2.52Predicted hydrolase of the HAD superfamily
05SSU1264 -R−2.04Predicted SAM-dependent methyltransferase
05SSU1399 -R−2.24hypothetical protein
05SSU1496 -R−2.00Predicted permease
05SSU1668 -R−2.08Hemolysins and related proteins containing CBS domains
Function unknown
05SSU1690 -S−2.92SAM-dependent methyltransferase
05SSU1707 -S−2.07Uncharacterized protein conserved in bacteria
05SSU0875 -S−2.33Uncharacterized protein conserved in bacteria
Intracellular trafficking, secretion and vesicular transport
05SSU0090 -U4.38Preprotein translocase subunit SecY
05SSU1965 -U−2.22unknown protein
Defense mechanisms
05SSU1450 -V−2.20Type I restriction enzyme EcoKI specificity protein (S protein)
Not in COGs
05SSU0473 -2.47Ribonucleases G and E
05SSU0474 -2.65Autotransporter adhesin
05SSU1792 -2.06Unknown protein
05SSU1793 -2.09hypothetical protein
05SSU1895 -2.08Uncharacterized conserved protein
05SSU2101 -7.61Unknown protein
05SSU0139 -−2.07hypothetical protein
05SSU0227 -−2.01Predicted dehydrogenase and related proteins
05SSU0870 -−3.09hypothetical protein
05SSU1082 -−2.75hypothetical protein
05SSU1274 -−2.11hypothetical protein
05SSU1403 sly−3.25Hemolysin, also named suilysin
05SSU1503 -−2.57putative enolase
05SSU1553 -−2.35Uracil phosphoribosyltransferase

Positive number represents fold change of upregulated gene, and negative number represents fold change of downregulated gene at the condition of licochalcone A treatment versus untreated reference condition.

Positive number represents fold change of upregulated gene, and negative number represents fold change of downregulated gene at the condition of licochalcone A treatment versus untreated reference condition.

Gene expression profile of Streptococcus suis treated by subinhibitory concentration of licochalcone A

The effect of licochalcone A on growth and properties of S.suis indicated its therapeutic potential for S.suis infection. To further explore the molecular mechanism of the effect, we compared the gene expression profile of S.suis serotype 2 strain 05ZYH33 that was cultured in the presence of subinhibitory concentration of licochalcone A and in the THB medium only. Of the 1930 genes whose mRNA expression was detected by microarray, 132 genes were differentially regulated upon licochalcone A treatment, including 78 genes (59%) up-regulated and 54 genes (41%) down-regulated. The 132 regulated genes could be assigned into 18 function categories (COG) based on the 05ZYH33 genome annotation as shown in Figure 4, which included many central biological functions such as metabolism, transcription, translation. To confirm the microarray data, 11 genes (Figure 5) were measured by quantitative RT-PCR. A strong positive correlation (r2 = 0.98) between the data obtained by microarray and quantitative RT-PCR suggested the reliability of the microarray data.
Figure 4

Differentially regulated genes (more than twofold changes) grouped by functional classification according to Streptococcus suis strain 05ZYH33 genome annotation.

The differentially regulated genes on the chromosome were divided into 18 categories. The number of genes up-regulated and down-regulated for each functional group was represented.

Figure 5

Comparison of microarray and RT-PCR data.

The relative transcriptional levels of 11 genes were determined by microarray and real-time RT-PCR. The fold changes in gene transcription in response to subinhibitory concentration of licochalcone A were logarithm-transformed in base 2. The real-time RT-PCR log2 values were plotted against the microarray data log2 values.

Differentially regulated genes (more than twofold changes) grouped by functional classification according to Streptococcus suis strain 05ZYH33 genome annotation.

The differentially regulated genes on the chromosome were divided into 18 categories. The number of genes up-regulated and down-regulated for each functional group was represented.

Comparison of microarray and RT-PCR data.

The relative transcriptional levels of 11 genes were determined by microarray and real-time RT-PCR. The fold changes in gene transcription in response to subinhibitory concentration of licochalcone A were logarithm-transformed in base 2. The real-time RT-PCR log2 values were plotted against the microarray data log2 values. To more thoroughly understand the effect of licochalcone A on S.suis, we tried to analyze the gene expression profile in the aspect of bacteria cell cycle control. As we know, Bacterial cells, like their eukaryotic counterparts, have a complex subcellular organization required to regulate and coordinate the cell cycle processes. Changes in growth rate must be accompanied by changes in the cell cycle to ensure that cell division stays coordinated with mass doubling, chromosome replication and chromosome segregation [21]. In the presence of licochalcone A, a distinguished change in S.suis gene expression profile was the up-regulated expression of ribosomal proteins. Among 54 total genes encoding ribosomal proteins, 23 (42.6%) genes (Table 2) were significantly up-regulated the expression. Besides, genes encoding DNA-directed RNA polymerase were up-regulated and the genes encoding transcriptional regulator were down-regulated. So, the level of gene transcription might be accelerated. These results indicated that S.suis might be preparing for the mass doubling. However, we found the genes responsible for DNA replication and cell division did not change or were down-regulated the expression. As we know, chromosome replication is coordinated with cell growth to ensure that: each origin, replication initiates once and only once per division cycle; at least one round of replication is completed and the nucleoids have segregated before the completion of cell division; and there are sufficient nutrients to support these processes. Nutrient availability is a key determinant for replication initiation [22]. The production of the initiation protein DnaA and other essential components of the replication machinery is proportional to carbon availability and growth rate. Amino acid starvation directly inhibits replication initiation through the production of guanosine tetraphosphate and guanosine pentaphosphate [23]. In the presence of licochalcone A, S.suis genes responsible for amino acid transport and metabolism were up-regulated. Among of 29 genes encoding ABC-type amino acid transport system, 11 genes (37.9%) were significantly up-regulated and no gene was significantly down-regulated. Besides, genes responsible for the anabolism of amino acid were up-regulated. For example, gene 05SSU0252 encoding glutamate dehydrogenase and gene 05SSU0791 encoding carbamoylphosphate synthase, were up-regulated more than two fold. However, genes responsible for the catabolism of amino acid were down-regulated. For example, gene 05SSU1709 encoding cysteine aminopeptidase C and gene 05SSU0345 encoding amidotransferase were down-regulated more than two fold. Taken together, we supposed that S.suis might be in the status of amino acid starvation and initiation of the replication was inhibited after treatment of licochalcone A. Division is initiated near the end of chromosome segregation by the formation of a cytokinetic ring at the nascent division site. The tubulin-like protein FtsZ serves as the foundation for assembly of this ring and is required for recruitment of the division machinery. After treated by licochalcone A, as shown in Table 2, S.suis cell division related genes encoded by 05SSU0417 (gpsB) and 05SSU0479 are significantly decreased expression two fold, and no gene was significantly up-regulated. Besides, among of 26 cell division related genes based on COG categories, 17 genes down-regulated the expression, 6 genes up-regulated their expression (data not shown).

Discussion

Licochalcone A is a retrochalcone isolated from the roots and rhizomes of Glycyrrhiza inflate. It is active against a wide range of Gram positive organisms but not against Gram negative bacteria and eukaryotes [24]. In this study, our results demonstrated that licochalcone A is active against S.suis with MICs of 4 µg/ml for S.suis serotype 2 strains and 8 µg/ml for S.suis serotype 7 strains. Besides, our results also demonstated that licochalcone A could change some properties of S.suis such as biofilm formation and suilysin secretion. Thus, licochalcone A might be a useful compound for the development of prevention and therapy agent for S.suis infection. Antimicrobial agents are often categorized according to their principal mechanism of action. Mechanisms include interference with cell wall synthesis (e.g., β-lactams and glycopeptide agents), inhibition of protein synthesis (macrolides and tetracyclines), interference with nucleic acid synthesis (fluoroquinolones and rifampin), inhibition of a metabolic pathway (trimethoprim-sulfamethoxazole), and disruption of bacterial membrane structure (polymyxins and daptomycin) [25]. The treatment of bacterial infections is increasingly complicated by the ability of bacteria to develop resistance to antimicrobial agents. Licochalcone A had been proved to have potent activity against some Gram positive bacteria, though its antimicrobial mechanism was not well elucidated. One possible mechanism is that licochalcone A could inhibit the bacterial respiratory electron transport chain at the site between Coenzyme Q and cytochrome c [26]. In this study, we tried to investigate the antimicrobial mechanism of licochalcone A in the aspect of bacterial cell cycle control. How organisms adjust their cell cycle dynamics to compensate for changes in nutritional conditions is an important outstanding question in bacterial physiology. Nutrient availability and metabolic status are coordinated with cell growth, chromosome replication and cell division. The gene expression profile of S.suis treated by licochalcone A showed that S.suis genes responsible for amino acid transport and anabolism of amino acid were up-regulated significantly and genes for catabolism of amino acid were down-regulated. These results indicated that S.suis cells might be in the status of amino acid starvation, while amino acid starvation directly inhibits replication initiation through the production of guanosine tetraphosphate and guanosine pentaphosphate. On the other hand, S.suis genes for cell division were also been down-regulated. Taken together, we supposed that licochalcone A might inhibit the growth of S.suis by controlling the replication initiation and cell division through the amino acid metabolism.

Conclusions

In this study, we tried to investigate the effect of licochalcone A on growth and properties of Streptococcus suis, an important emerging worldwide pig pathogen and zoonotic agent with rapid evolution of virulence and drug resistance. Our results demonstrated that licochalcone A could effectively inhibit the growth, biofilm formation and suilysin secretion of S.suis. Besides, we put forward a hypothesis to elucidate the antimicrobial mechanism of licochalcone A in the aspect of bacterial cell cycle control. Namely, licochalcone A might inhibit the growth of S.suis by controlling the replication initiation and cell division through amino acid metabolism. Our results demonstrated that licochalcone A might be a useful compound for the development of prevention and therapy agent for S.suis infection.

Materials and Methods

Ethics statement

All the experiments in the paper were conducted under the supervision of the Institutional Review Board of the Academy of Military Medical Sciences. All the bacterial isolates were isolated previously and kindly provided by the hospital, Institutes or Academy. No samples were collected from patients directly in this study and therefore the study was exempt from obtaining informed consent. All relevant ethical safeguards have been met in the experiments.

Streptococcus suis and culture conditions

S.suis strain 05ZYH33 (previously isolated from an STSS patient with S.suis infection) and other S.suis strains (listed in Table 1) were used in this study. The microorganism was maintained on Columbia blood agar (BioMerieux) supplemented with 5% sheep blood, and the bacteria were cultured in Todd-Hewitt broth (THB) (Becton, Dickinson and Co.) at 37°C.

Licochalcone A

Licochalcone A was purchased from Sigma-Aldrich, Inc. and prepared in 99% ethanol at a final concentration of 10 mg/ml and stored at 4°C protected from light at least 24 h to allow sterilization.

Growth Curves

S.suis strain 05ZYH33 was inoculated into THB medium and grown for 12 h at 37°C. And then aliquots of 50 µl of the cultures were inoculated into 5 ml fresh THB medium containing licochalcone A at 0, 0.5, 1.0, 2.0, 4.0 µg/ml in test tubes. Bacteria were further cultured at 37°C and cell growth was monitored spectrophotometrically (OD600 nm at 1 h intervals). 50 µl samples of each culture were collected at 1 h intervals after the addition of Licochalcone A and plated onto THB agar to accurately determine the viable bacteria.

Determination of minimal inhibitory concentration (MIC)

MICs of different S.suis strains were estimated as previously described [24]. Briefly, S.suis strain was inoculated into THB medium and grown to mid-log phase (OD600 nm 0.8) at 37°C, aliquots of 50 µl culture of bacteria were inoculated into 5 ml fresh THB medium containing licochalcone A at 0, 0.5, 1.0, 2.0, 4.0 µg/ml in test tubes (For S.suis serotype 7, the tested concentration of licochalcone A was up to 8.0 µg/ml) and cultured further for 24 h. The MIC was defined as the lowest concentration at which no visible growth. All assays were performed in triplicate and three independent experiments were carried out.

Effect of licochalcone A on biofilm formation

The effect of licochalcone A on S.suis biofilm formation was assessed by a modification of the methods originally described [14], [27]. S.suis strain 05ZYH33 was cultured in broth containing (w/v) 0.5% glucose, 2% peptone, 0.3% K2HPO4, 0.2% KH2PO4, 0.01% MgSO4·7H2O, 0.002% MnSO4·6H2O, and 0.5% NaCl. Human fibrinogen was also added at concentration of 5 mg/ml to induce biofilm formation. An overnight culture of S.suis was diluted in fresh culture broth to obtain an optical density at 600 nm (OD600) of 0.2. Samples (100 µl) were added to the 96-well polystyrene tissue culture plate containing 100 µl of culture medium. Licochalcone A was tested at final concentrations of 2, 3, and 4 µg/ml. After incubation for 18 h or 24 h at 37°C, medium and free-floating bacteria were removed by aspiration and the wells were washed three times with 50 mM phosphate-buffered saline (pH 7.2, PBS). The biofilms were stained with 0.04% crystal violet (100 µl) for 10 min. The wells were washed three times with PBS to remove unbound crystal violet dye and dried for 2 h at 37°C. After adding 100 µl 95% (v/v) ethanol to each well, the plate was shaken for 10 min to release the stain from the biofilms and recorded the absorbance at 550 nm (OD550). All biofilm assays were run in triplicate and the means ± standard deviations of two independent experiments were calculated.

Titration of hemolytic activity

The suilysin content in S.suis culture supernatant was evaluated by titration of its hemolytic activity as previous described with some modifications [28], [29]. Briefly, serial twofold dilutions of test samples were prepared in polystyrene deep-well titer plates with PBS as the diluent. Subsequently, an equal amount of human red blood cells (RBC) (final concentration of RBS: 2%) washed twice in the solution mentioned above, was added to each well. Following incubation for 1 h at 37°C, the mixtures were sedimented by centrifugation (1500 g for 10 min), supernatants were transferred to polystyrene microplates and measured at 540 nm with a microELISA reader.

S.suis whole-genome microarray experiments

S.suis strain 05ZYH33 were grown in THB with subinhibitory concentrations (0.25 µg/ml) of LicA to the postexponential growth phase, other aliquots of S.suis strain 05ZYH33 without LicA cultured in the same condition were used as control. Immediately before harvesting, 1 volume of bacterial culture was mixed with 2 volume of RNAprotect Bacteria Reageat (Qiagen) by vortexing for 5 s and incubated for 5 min at room temperature to minimize RNA degradition. Then, bacteria were harvested by centrifugation (5000 g for 5 min at 4°C) and total bacterial RNA was extracted by using the MasterPure™ RNA Purification kit (Epicenter). Total RNA was isolated from four replicate cultures at each condition. Microarray Experiments were performed as previously described [30], [31]. Briefly, Total RNA was used to synthesize cDNA in the presence of aminoallyl-dUTP and random hexamer primers. The aminoally-modified cDNA was then labeled with Cy5 or Cy3 dye. Accordingly, four dual-fluorescence-labeled cDNA probes were prepared to hybridize with four slides, respectively. Pairwise comparisons were made using dye swaps to avoid labeling bias. And, the image signals on the slides were captured by using a GenePix personal 4100A microarray scanner. The scan images were processed and data were further analyzed by using GenePix Pro 4.1 software combined with Microsoft Excel software. Spots were analyzed by adaptive quantitation, and the local background was subsequently substracted. Spots with background-corrected signal intensity (median) in both channels of less than twofold of background intensity (median) were rejected from further analysis. Data normalization was performed on the remaining spots by total intensity normalization methods. The normalized log2 ratio of test/reference signal for each spot was recorded. Significant changes in gene expression were identified using SAM software. After SAM analysis, only genes with at least 2-fold changes in expression were collected for further analysis. The microarray data (GSE46666) had been deposited in Gene Expression Omnibus (GEO).

Real-time quantitative PCR analysis

Gene-specific primers (Listed in Table 3) were designed to produce an amplicon of 100–150 bp for each gene tested. The contaminating DNA in RNA samples was removed by using Amibion's DNA-free Kit (Applied Biosystems, Foster City, CA) cDNAs were generated by random hexamer primers. Using three independent cultures and RNA preparations, real-time RT-PCR was performed in triplicate using the Stepone Plus system together with the SYBR Green master mix. On the basis of the standard curves of 16S rRNA expression, the relative mRNA level was determined by calculating the threshold cycle (ΔCt) of each gene using the classic ΔCt method. Negative controls were performed by using cDNA generated without reverse transcriptase as templates. Reactions containing primer pairs without template were also included as blank controls. The 16S rRNA gene was used as an internal control to normalize all the other genes.
Table 3

Genes and oligonucleotides used in validation of DNA microarray data.

GeneForward PrimerReverse Primer
SSU05_0074 ACGGTGGTGGTGAAGGTAAAGC TGGTTGCGACGACGAACGATAAG
SSU05_0075 AGGACAACGAACACGGTAAC CAAATGCTCATCGACGAAAGG
SSU05_0076 AGCAGACGCAATCGCAATC GCTTCGCTGACTACCAAGTTAG
SSU05_0083 GGCTTCCGTCTTCGTGAG AAGTGAAACTGTAACCAATTTGTC
SSU05_0085 TTGCCTGCTGGTGTTGAG GTTTGGACGGTGAAGAGTTAC
SSU05_0087 ACAATCCCTCACGAAGTTC AAGTCACATCTGCGATACC
SSU05_0089 GTGGTACATCATCAGGTAACG GGAAGACGACGGAACAATG
SSU05_0279 GCTACTCTGTTGACGGTGGTATG AGTAACGCCAGCACAAGTGATAG
SSU05_0280 TGTCACCTGTTATTGCCGTCTTG TTCTGCGTCTTCCGTATGAATAGC
SSU05_0479 AGTGCTGGCGTCAAAGATGG TGAAGAAGGTTGGCAGGTAATCC
SSU05_1759 ACTATACGAAGGCTGAACCAATC CTACGAGCATAGAGCACTAAGG
  30 in total

1.  Mechanism of regulation of transcription initiation by ppGpp. I. Effects of ppGpp on transcription initiation in vivo and in vitro.

Authors:  M M Barker; T Gaal; C A Josaitis; R L Gourse
Journal:  J Mol Biol       Date:  2001-01-26       Impact factor: 5.469

Review 2.  Mechanisms of biofilm resistance to antimicrobial agents.

Authors:  T F Mah; G A O'Toole
Journal:  Trends Microbiol       Date:  2001-01       Impact factor: 17.079

3.  Production of suilysin, the thiol-activated haemolysin of Streptococcus suis, by field isolates from diseased pigs.

Authors:  A A Jacobs; A J van den Berg; J C Baars; B Nielsen; L W Johannsen
Journal:  Vet Rec       Date:  1995-09-16       Impact factor: 2.695

4.  Antibacterial activity of licochalcone A against spore-forming bacteria.

Authors:  Ryo-Ichi Tsukiyama; Harumi Katsura; Nozomu Tokuriki; Makio Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  Distribution and genetic diversity of suilysin in Streptococcus suis isolated from different diseases of pigs and characterization of the genetic basis of suilysin absence.

Authors:  S J King; P J Heath; I Luque; C Tarradas; C G Dowson; A M Whatmore
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

6.  Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis.

Authors:  A A Jacobs; P L Loeffen; A J van den Berg; P K Storm
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection.

Authors:  M Chen; T G Theander; S B Christensen; L Hviid; L Zhai; A Kharazmi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Occupational exposure to Streptococcus suis type 2.

Authors:  I D Robertson; D K Blackmore
Journal:  Epidemiol Infect       Date:  1989-08       Impact factor: 2.451

9.  Up-regulation of ICAM-1, CD11a/CD18 and CD11c/CD18 on human THP-1 monocytes stimulated by Streptococcus suis serotype 2.

Authors:  D Al-Numani; M Segura; M Doré; M Gottschalk
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 10.  Quaternized chitosan as an antimicrobial agent: antimicrobial activity, mechanism of action and biomedical applications in orthopedics.

Authors:  Honglue Tan; Rui Ma; Chucheng Lin; Ziwei Liu; Tingting Tang
Journal:  Int J Mol Sci       Date:  2013-01-16       Impact factor: 5.923

View more
  7 in total

Review 1.  Role of Licochalcone A in Potential Pharmacological Therapy: A Review.

Authors:  Meng-Ting Li; Long Xie; Hai-Mei Jiang; Qun Huang; Rong-Sheng Tong; Xiang Li; Xin Xie; Hong-Mei Liu
Journal:  Front Pharmacol       Date:  2022-05-23       Impact factor: 5.988

2.  Toll-like receptor 4 confers inflammatory response to Suilysin.

Authors:  Lili Bi; Yaya Pian; Shaolong Chen; Zhiqiang Ren; Peng Liu; Qingyu Lv; Yuling Zheng; Shengwei Zhang; Huaijie Hao; Yuan Yuan; Yongqiang Jiang
Journal:  Front Microbiol       Date:  2015-06-26       Impact factor: 5.640

3.  Effects of Suilysin on Streptococcus suis-Induced Platelet Aggregation.

Authors:  Shengwei Zhang; Junping Wang; Shaolong Chen; Jiye Yin; Zhiyuan Pan; Keke Liu; Lin Li; Yuling Zheng; Yuan Yuan; Yongqiang Jiang
Journal:  Front Cell Infect Microbiol       Date:  2016-10-17       Impact factor: 5.293

4.  Licochalcone A Prevents Platelet Activation and Thrombus Formation through the Inhibition of PLCγ2-PKC, Akt, and MAPK Pathways.

Authors:  Li-Ming Lien; Kuan-Hung Lin; Li-Ting Huang; Mei-Fang Tseng; Hou-Chang Chiu; Ray-Jade Chen; Wan-Jung Lu
Journal:  Int J Mol Sci       Date:  2017-07-12       Impact factor: 5.923

Review 5.  Traditional Uses, Pharmacological Effects, and Molecular Mechanisms of Licorice in Potential Therapy of COVID-19.

Authors:  Qian-Hui Zhang; Hao-Zhou Huang; Min Qiu; Zhen-Feng Wu; Zhan-Chang Xin; Xin-Fu Cai; Qiang Shang; Jun-Zhi Lin; Ding-Kun Zhang; Li Han
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

6.  Antioxidant Activity and Antibacterial Effects on Clinical Isolated Streptococcus suis and Staphylococcus intermedius of Extracts from Several Parts of Cladogynos orientalis and Their Phytochemical Screenings.

Authors:  Pongtip Sithisarn; Piyanuch Rojsanga; Patchima Sithisarn; Sumet Kongkiatpaiboon
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-11       Impact factor: 2.629

7.  In Vitro and In Vivo Antifungal Activity of Lichochalcone-A against Candida albicans Biofilms.

Authors:  Dalia Seleem; Bruna Benso; Juliana Noguti; Vanessa Pardi; Ramiro Mendonça Murata
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.